Carmona Araújo Ana, Fernandes Elisabete, Franco Ruivo Inês, Machado Maria do Céu, Faria Vaz António, Furtado Cláudia
Direção de Informação e Planeamento Estratégico. Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (INFARMED). Lisboa; Instituto de Investigação do Medicamento (iMed.ULisboa). Faculdade de Farmácia. Universidade de Lisboa. Lisboa. Portugal.
Direção de Informação e Planeamento Estratégico. Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (INFARMED). Lisboa. Portugal.
Acta Med Port. 2023 Dec 4;36(12):792-801. doi: 10.20344/amp.19254. Epub 2023 Jul 7.
Like in other countries, the age pyramid in Portugal has been changing considerably, with a substantial increase in the size of the older population and a significant reduction in the number of young people. With aging, co-occurrence of several conditions becomes frequent, often leading to the use of multiple medications (polypharmacy). Polypharmacy in the older population is particularly relevant considering the physiological changes of the ageing process, which increase the risk of drug interactions, poor adherence to treatment, and adverse drug reactions, especially in the oldest-old population (85 years or older). As the size of the older population is likely to increase significantly, it is important to characterize the pattern of medicines' use by the elderly while also identifying cases of polypharmacy in order to obtain evidence that can be used to develop specific measures to tackle the high prevalence of use and its associated risks. To this end, the aim of this study was to characterize medication use by older individuals in Portugal.
Cross-sectional study with data from the National Health System's Control and Monitoring Center on reimbursed medicines that were prescribed and dispensed to individuals aged 65 years or older in 2019 in all community pharmacies of the Portuguese mainland. We performed a demographic and geographic analysis of the data by international nonproprietary name and therapeutic group. The number of reimbursed packages and the number of reimbursed packages per capita were the metrics used (data from Instituto Nacional de Estatística).
A higher consumption of medicines was observed in women, increasing with age, except in the oldest olds, in which the sex difference tended to shrink. Use per capita showed an opposite trend, with the oldest-old men surpassing the oldest-old women (mean reimbursed packages: 55.5 in men versus 55.1 in women). In women, consumption was led by cardiovascular medicines (31%), followed by central nervous system medications (30%) and antidiabetics (13%); in men, 37% of TOP 10 consumption was due to cardiovascular medications, antidiabetics (16%) and drugs for benign prostatic hypertrophy (14%).
In the elderly, there were sex differences in the pattern of medicines' use, and there were also significant age-related differences in 2019. To the best of our knowledge, our study is the first nationwide analysis of reimbursed medicines' consumption data in the elderly, which is essential to characterize the use of medicines in this age group in Portugal.
与其他国家一样,葡萄牙的年龄金字塔也在发生显著变化,老年人口规模大幅增加,而年轻人数量大幅减少。随着年龄增长,多种疾病并发的情况变得频繁,常常导致使用多种药物(多重用药)。考虑到衰老过程中的生理变化,老年人群中的多重用药尤其值得关注,这些生理变化会增加药物相互作用、治疗依从性差和药物不良反应的风险,尤其是在高龄人群(85岁及以上)中。由于老年人口规模可能会显著增加,重要的是要描述老年人的用药模式,同时识别多重用药的情况,以便获得可用于制定具体措施来应对高用药率及其相关风险的证据。为此,本研究的目的是描述葡萄牙老年人的用药情况。
采用横断面研究,数据来自国家卫生系统控制与监测中心,涉及2019年在葡萄牙大陆所有社区药房为65岁及以上个人开具和配发的报销药品。我们按国际非专利名称和治疗组对数据进行了人口统计学和地理分析。使用的指标是报销药品包装数量和人均报销药品包装数量(数据来自国家统计局)。
观察到女性的药品消费量较高,随年龄增长而增加,但在高龄人群中,性别差异趋于缩小。人均用药量呈现相反趋势,高龄男性超过高龄女性(平均报销药品包装数量:男性为55.5,女性为55.1)。在女性中,消费量最高的是心血管药物(31%),其次是中枢神经系统药物(30%)和抗糖尿病药物(13%);在男性中,十大消费药品中37%是心血管药物、抗糖尿病药物(16%)和治疗良性前列腺增生的药物(14%)。
在老年人中,用药模式存在性别差异,2019年也存在显著的年龄相关差异。据我们所知,我们的研究是对老年人报销药品消费数据的首次全国性分析,这对于描述葡萄牙该年龄组的用药情况至关重要。